Activist Investor Calls For Sanity As FTC Rejects Grail-Illumina Deal
Executive Summary
Illumina faces a difficult decision now that the US FTC has formally rejected its attempt to re-acquire Grail, the sequencing company it originally sold in 2016. The FTC and European regulators say the merger would stifle competition but the company plans to appeal the ruling.
You may also be interested in...
FTC’s Khan Addresses PBMs, Amgen-Horizon Merger, At Contentious Congressional Hearing
Republican members of the House Judiciary Committee question FTC policies under Khan’s leadership, including its challenge of the Amgen-Horizon and Illumina-Grail mergers, as well as a proposal to require more information in pre-notification submissions. ‘You’re a bully,’ Representative Issa tells her.
CEO Resignation Raises Doubts About Illumina’s Commitment To Grail
Francis deSouza resigned as CEO and chairman of Illumina just a few weeks after winning the support of shareholders. General counsel Charles Dadswell will take over as interim CEO.
Illumina Appeals FTC Decision, Grail Swings And Misses
Illumina has formally appealed the FTC’s decision to block its acquisition of Grail, just days after Grail mistakenly sent letters to patients suggesting they could have cancer.